Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 30;28(1):716-725.
doi: 10.3390/curroncol28010070.

Cost Minimization Analysis of Hypofractionated Radiotherapy

Hannah L Yaremko  1 , Gordon E Locke  2 , Ronald Chow  3   4 , Michael Lock  4 , Robert Dinniwell  4 , Brian P Yaremko  4
Affiliations

Cost Minimization Analysis of Hypofractionated Radiotherapy

Hannah L Yaremko et al. Curr Oncol. .

Abstract

Early-stage breast cancer patients comprise a large proportion of patients treated with radiotherapy in Canada. Proponents have suggested that five-fraction hypofractionated radiotherapy for these patients would result in significant cost savings. An assessment of this argument is thus warranted. The FAST-Forward and UK FAST clinical trials each demonstrated that their respective hypofractionated regimens provided equivalent outcomes compared with standard regimens. Thus, a cost-minimization analysis was performed to quantify the potential savings associated with these regimens, which were designated as FAST-Forward 1 (26 Gy/5 fractions/1 week) and FAST-Forward 2 (27 Gy/5 fractions/1 week), and UK FAST 1 (28.5 Gy/5 fractions/5 weeks) and UK FAST 2 (30 Gy/5 fractions/5 weeks). A standard regimen of 42.5 Gy/16 fractions/5 weeks was also included. A comprehensive model of radiotherapy costs for a Canadian cancer centre was created. Time, labour costs, and capital costs were calculated for each regimen and applied using established measures. The total costs per patient for the FAST-Forward trials were $851.77 for FAST-Forward 1 and $874.77 for FAST-Forward 2, providing a total savings of $487.99 and $464.99, respectively. Similarly, the total costs per patient for the FAST trials were $979.75 for UK FAST 1 and $1017.70 for UK FAST 2, providing savings of $360.01 and $322.06, respectively. Following the FAST-Forward 1 regimen results in the greatest reduction of infrastructure and human resources costs at 36.42% compared with the standard. Sensitivity analysis shows a maximum per-patient costs savings ranging from $474.60 to $508.53 for the FAST-Forward 1 trial, which translates to an annual savings of $174,700/year locally and $2.06 million/year province-wide, based on a moderate-to-large size department workload. Compared with a standard radiotherapy regimen, all FAST-Forward and UK FAST hypofractionated regimens provide cost savings for the treatment of early-stage breast cancer. The cost savings associated with each of these equivalent regimens can be directly calculated; activities in this model can easily be adjusted to account for cost variations, allowing other centres to calculate cost impacts specific to their own centres.

Keywords: breast cancer; cost minimization analysis; hypofractionation; radiation.

PubMed Disclaimer

Conflict of interest statement

Some data and analytic method used for this comparison were used by the authors in a previous publication (Cureus, 5(8). http://doi.org/10.7759/).

References

    1. Darby S.C., McGale P., Correa C.R., Taylor C.A., Arriagada R., Clarke M., Cutter D., Davies C., Ewertz M., Godwin J., et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378:1707–1716. doi: 10.1016/s0140-6736(11)61629-2. - DOI - PMC - PubMed
    1. Bartelink H., Horiot J.-C., Poortmans P., Struikmans H., Bogaert W.V.D., Barillot I., Fourquet A., Borger J., Jager J., Hoogenraad W., et al. Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation. N. Engl. J. Med. 2001;345:1378–1387. doi: 10.1056/NEJMoa010874. - DOI - PubMed
    1. Théberge V., Whelan T., Shaitelman S.F., Vicini F.A. Altered Fractionation: Rationale and Justification for Whole and Partial Breast Hypofractionated Radiotherapy. Semin. Radiat. Oncol. 2011;21:55–65. doi: 10.1016/j.semradonc.2010.08.007. - DOI - PubMed
    1. Haviland J.S., Owen J.R., Dewar J.A., Agrawal R.K., Barrett J.M., Barrett-Lee P.J., Dobbs H.J., Hopwood P., Lawton P.A., Magee B.J., et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–1094. doi: 10.1016/S1470-2045(13)70386-3. - DOI - PubMed
    1. Whelan T.J., Pignol J.-P., Levine M.N., Julian J.A., MacKenzie R., Parpia S., Shelley W., Grimard L., Bowen J., Lukka H., et al. Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer. N. Engl. J. Med. 2010;362:513–520. doi: 10.1056/NEJMoa0906260. - DOI - PubMed

LinkOut - more resources